Literature DB >> 26115201

Severe childhood Guillain-Barré syndrome associated with Mycoplasma pneumoniae infection: a case series.

Patrick M Meyer Sauteur1,2,3, Joyce Roodbol4,5, Annette Hackenberg6, Marie-Claire Y de Wit5, Cornelis Vink2,7, Christoph Berger3, Enno Jacobs8, Annemarie M C van Rossum1, Bart C Jacobs4,9.   

Abstract

We report seven children with recent Mycoplasma pneumoniae infection and severe Guillain-Barré syndrome (GBS) that presented to two European medical centres from 1992 to 2012. Severe GBS was defined as the occurrence of respiratory failure, central nervous system (CNS) involvement, or death. Five children had GBS, one Bickerstaff brain stem encephalitis (BBE), and one acute-onset chronic inflammatory demyelinating polyneuropathy (A-CIDP). The five patients with severe GBS were derived from an original cohort of 66 children with GBS. In this cohort, 17 children (26%) had a severe form of GBS and 47% of patients with M. pneumoniae infection presented with severe GBS. Of the seven patients in this case series, five were mechanically ventilated and four had CNS involvement (two were comatose). Most patients presented with non-specific clinical symptoms (nuchal rigidity and ataxia) and showed a rapidly progressive disease course (71%). Antibodies against M. pneumoniae were detected in all patients and were found to be intrathecally synthesised in two cases (GBS and BBE), which proves intrathecal infection. One patient died and only two patients recovered completely. These cases illustrate that M. pneumoniae infection in children can be followed by severe and complicated forms of GBS. Non-specific clinical features of GBS in such patients may predispose a potentially life-threatening delay in diagnosis.
© 2015 Peripheral Nerve Society.

Entities:  

Keywords:  Bickerstaff brain stem encephalitis; Mycoplasma pneumoniae; acute-onset chronic inflammatory demyelinating polyneuropathy; central nervous system infection; children

Mesh:

Year:  2015        PMID: 26115201     DOI: 10.1111/jns.12121

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  7 in total

Review 1.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

Review 2.  [Clinical implications of the genus Mycoplasma].

Authors:  D Gómez Rufo; E García Sánchez; J E García Sánchez; M García Moro
Journal:  Rev Esp Quimioter       Date:  2021-03-18       Impact factor: 1.553

Review 3.  Refractory Mycoplasma pneumoniae pneumonia with concomitant acute cerebral infarction in a child: A case report and literature review.

Authors:  Xingnan Jin; Yingxue Zou; Jia Zhai; Jie Liu; Bing Huang
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

4.  Concomitant Guillain-Barre syndrome with COVID-19: a case report.

Authors:  Nuvia Mackenzie; Eva Lopez-Coronel; Alberto Dau; Dieb Maloof; Salvador Mattar; Jesus Tapia Garcia; Briyis Fontecha; Cristina M Lanata; Hernan Felipe Guillen-Burgos
Journal:  BMC Neurol       Date:  2021-03-23       Impact factor: 2.474

5.  The Correlation Among the Immunoglobulin G Synthesis Rate, IgG Index and Albumin Quotient in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Retrospective Case-Control Study.

Authors:  Yu Tu; Xuan Gong; Yuanyuan Zhang; Jiewei Peng; Wenyan Zhuo; Xueying Yu
Journal:  Front Neurol       Date:  2021-12-17       Impact factor: 4.003

Review 6.  Infection with and Carriage of Mycoplasma pneumoniae in Children.

Authors:  Patrick M Meyer Sauteur; Wendy W J Unger; David Nadal; Christoph Berger; Cornelis Vink; Annemarie M C van Rossum
Journal:  Front Microbiol       Date:  2016-03-23       Impact factor: 5.640

Review 7.  Mycoplasma pneumoniae: A Potentially Severe Infection.

Authors:  Bharat Bajantri; Sindhaghatta Venkatram; Gilda Diaz-Fuentes
Journal:  J Clin Med Res       Date:  2018-06-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.